Trial By Fire Solutions, an eClinical solution provider specializing in clinical study management applications, announced that PRC Clinical, a privately held Contract Research Organization (CRO), has selected SimpleCTMS to complement existing clinical trial management solutions as an integrated part of their portfolio of services.
Through this strategic collaboration, PRC Clinical will incorporate SimpleCTMS into their suite of eClinical services. The addition of SimpleCTMS compliments their existing provider relationships to rapidly execute a full suite of clinical services while maintaining their high level of quality standards.
"SimpleCTMS is a very robust and intuitive system with real-time information at our fingertips, comprehensive reports and amazing customer support," said Curtis Head, PRC Clinical's President. "The PRC Clinical team is delighted to add this powerful tool to all of our studies to increase our trial management effeciency and value to sponsors."
"Having worked along side the PRC Clinical team for many years, we are delighted they chose SimpleCTMS. With their strong reputation as a CRO, they are a highly complementary addition to our diverse client base. PRC Clinical recognized the immediate benefits they could gain from SimpleCTMS, as well as the ability to mold the system to fit their growing client base and wide variety of clinical studies," said Nancy Cecchettini, Co-founder and Chief Product Officer at Trial By Fire Solutions.
In addition to using SimpleCTMS for core study management tasks, the CTMS will provide compelling performance visualizations and data transparency to PRC Clinical's prospective and existing client base. SimpleCTMS will easily integrate with existing eClinical systems to leverage external data and centralize tracking of key study metrics.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.